Integrase strand transfer inhibitors (INSTI) are drugs whose mechanism of action consists of blocking the integration process of the proviral DNA to the host DNA by binding to the catalytic site of the viral integration and thus preventing its replication. Currently it has the approval of INSTI of first generation, two of second generation and in process of approval of a third of second generation. The two generations has similitude in its mechanisms of action, changes in its structures that modify its genetic barrier, but keeping his security and effectiveness profile. Since the approval of INSTI´s in 2007 to date, multiple clinical studies have been carried out, whose results have allowed us to advance in the knowledge of their effectiveness in different clinical scenarios; (naive patients, experienced patients, simplification and prophylaxis schemes, as well as in the knowledge of their profile of resistance mutations). In the present article, we made a review of the members of this family of antiretrovirals (ARV).
CITATION STYLE
Gualtero, S., Valderrama, S., Quiroga, C., Garzon, J., Lowenstein, E., Tamara, R., … Méndez, M. L. L. (2019). Integrase strand transfer inhibitors: Bases for its use in the clinical practice. Infectio, 23, 106–128. https://doi.org/10.22354/in.v23i1.765
Mendeley helps you to discover research relevant for your work.